Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.
Joel M KremerClifton O BinghamLaura C CappelliJeffrey D GreenbergAnn M MadsenJamie GeierJose L RivasAlina M OnofreiChristine J BarrDimitrios A PappasHeather J LitmanKimberly J DandreoAndrea B ShapiroCarol A ConnellArthur KavanaughPublished in: ACR open rheumatology (2021)
In this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators.